Related Experiment Video
Updated: Feb 7, 2026

Chuzhen Therapy as a Non-Invasive Traditional Chinese Therapy for Neck Pain
Published on: June 6, 2025
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Maria-Theresa Krauth1, Sonja Burgstaller2, Veronika Buxhofer-Ausch3
1Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University Vienna, Vienna, Austria. maria.krauth@meduniwien.ac.at.
Abstract:
The oral Janus associated kinase (JAK1/2) inhibitor ruxolitinib has been available for treatment of patients with intermediate or high-risk myelofibrosis in Europe since 2012. Since its introduction, the expertise of prescribing doctors with respect to ruxolitinib function, efficacy and adverse effects has consistently been augmented, resulting in therapy modalities that are better tailored to individual patients as well as in increased safety of the treatment. The present consensus on ruxolitinib therapy management has been elaborated by Austrian experts in myeloproliferative neoplasms in line with international treatment guidelines. Our recommendations aim to contribute to an improved management of patients with myelofibrosis treated with ruxolitinib.
Related Concept Videos
Gene Therapy
Group Therapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
Drug Therapy
Antianxiety Medications
Cognitive Therapy

